435 related articles for article (PubMed ID: 24687301)
1. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
[TBL] [Abstract][Full Text] [Related]
2. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
[TBL] [Abstract][Full Text] [Related]
6. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
[TBL] [Abstract][Full Text] [Related]
7. A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization.
Manko J; Walter-Croneck A; Jawniak D; Grzasko N; Gorska-Kosicka M; Cioch M; Dmoszynska A
Pharmacol Rep; 2014 Apr; 66(2):239-42. PubMed ID: 24911076
[TBL] [Abstract][Full Text] [Related]
8. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
10. Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
Schmitt M; Hoffmann JM; Lorenz K; Publicover A; Schmitt A; Nagler A
Vox Sang; 2016 Aug; 111(2):178-86. PubMed ID: 27509033
[TBL] [Abstract][Full Text] [Related]
11. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor.
Lefrère F; Brignier AC; Elie C; Ribeil JA; Bernimoulin M; Aoun C; Dal Cortivo L; Delarue R; Hermine O; Cavazzana-Calvo M
Adv Ther; 2011 Apr; 28(4):304-10. PubMed ID: 21400232
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience.
Islami MM; Khan MA; Aseeri MA; Alshamrani MA; Alnatsheh A; Alamoudi S; Alzahrani AA
Ann Transplant; 2023 Mar; 28():e938585. PubMed ID: 36864713
[TBL] [Abstract][Full Text] [Related]
13. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation.
Schmitt M; Publicover A; Orchard KH; Görlach M; Wang L; Schmitt A; Mani J; Tsirigotis P; Kuriakose R; Nagler A
Theranostics; 2014; 4(3):280-9. PubMed ID: 24505236
[TBL] [Abstract][Full Text] [Related]
15. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF.
Demirer T; Ayli M; Ozcan M; Gunel N; Haznedar R; Dagli M; Fen T; Genc Y; Dincer S; Arslan O; Gürman G; Demirer S; Ozet G; Uysal A; Konuk N; Ilhan O; Koc H; Akan H
Br J Haematol; 2002 Feb; 116(2):468-74. PubMed ID: 11841454
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety of Short-Term Administration of Filgrastim (rhG-CSF) and Leukophresis Procedure in Healthy Children: Application of Peripheral Blood Stem Cell Collection in Pediatric Donors.
Behfar M; Faghihi-Kashani S; Hosseini AS; Ghavamzadeh A; Hamidieh AA
Biol Blood Marrow Transplant; 2018 Apr; 24(4):866-870. PubMed ID: 29284143
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
[TBL] [Abstract][Full Text] [Related]
19. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
[TBL] [Abstract][Full Text] [Related]
20. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
Pham T; Patil S; Fleming S; Avery S; Walker P; Wei A; Curtis D; Stuart G; Klarica D; O'Brien M; Morris K; Das T; Bollard G; Muirhead J; Coutsouvelis J; Spencer A
Transfusion; 2015 Nov; 55(11):2709-13. PubMed ID: 26173921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
